QHP Capital Acquires Applied StemCell

HealthQuest Capital and Great Point Partners Invest Growth Equity in Cellipont Bioservices; Darren Head Named CEO

October 7, 2024

Biotechnology

Cellipont Bioservices named Darren Head as CEO and announced a minority growth equity investment from HealthQuest Capital, with majority investor Great Point Partners also participating. The capital and leadership transition are intended to support Cellipont’s expansion of cell-therapy CDMO capabilities and operational growth.

QHP Capital Acquires AutoCruitment

October 27, 2022

Healthcare Services

QHP Capital, the management company for NovaQuest Private Equity, has acquired AutoCruitment, a digital patient recruitment platform that helps pharma, biotech and CROs identify, screen and recruit patients for clinical trials. Monroe Capital provided a senior credit facility to support the acquisition, and QHP says the investment will support continued growth and capability expansion of AutoCruitment's digital patient recruitment offerings.

Ampersand Capital Partners Invests in Genezen Laboratories

January 5, 2021

Biotechnology

Ampersand Capital Partners has made a majority growth-equity investment in Genezen Laboratories, a cell and gene therapy CDMO, to fund completion of a 25,000 sq. ft. cGMP lentiviral vector production facility and expand process development and analytical testing capabilities. The capital will support Genezen's capability expansion across upstream/downstream processing, analytical testing, and cGMP vector production to serve early‑phase and growth-stage cell and gene therapy developers.

Cycle Pharmaceuticals (Cycle Group) Acquires Applied Therapeutics, Inc.

February 3, 2026

Pharmaceuticals

Cycle Group Holdings Limited (Cycle Pharmaceuticals) has completed the acquisition of NASDAQ-listed Applied Therapeutics, a clinical-stage biopharmaceutical company focused on novel CNS-penetrant therapies for rare metabolic diseases. The transaction was funded from Cycle's cash on hand and brings Applied's lead candidate govorestat and rare-disease pipeline into Cycle's rare metabolic disease platform.

Century Therapeutics Acquires Clade Therapeutics; Raises $60M Private Placement Led by Bain Capital Life Sciences

April 11, 2024

Biotechnology

Century Therapeutics agreed to acquire privately held Clade Therapeutics for approximately $35 million in upfront consideration (plus a potential $10 million milestone) to expand its iPSC-derived cell therapy pipeline and next-generation Allo-EvasionTM platform. Concurrently, Century completed a roughly $60 million private placement led by Bain Capital Life Sciences and several institutional investors to support expanded autoimmune development of its lead program CNTY-101 and extend cash runway into 2026.

Great Point Partners Makes Growth Investment in iXCells Biotechnologies

September 29, 2022

Biotechnology

Great Point Partners, a Greenwich, CT-based healthcare-focused private investment firm, has made a growth investment in San Diego-based iXCells Biotechnologies. The capital will be used to expand iXCells' operational capacity, broaden its product and service offering (including bioanalytical capabilities) and support growth into adjacent high-growth end markets such as personalized medicine and rare disease research.